French healthcare developer Enterome Bioscience has raised €10m in the first tranche of a Series B fund raising.
The funding has been led by the company’s existing investors, Seventure, from its new Health for Life Capital fund, and Lundbeckfond Ventures, and is backed by Omnes Capital.
The funds raised will be used by Enterome to undertake the R&D and business development activities needed to develop the quantitative and functional analysis of the gut microbiome in relation to health and disease.
Isabelle de Cremoux, CEO, Seventure, said, “Enterome is a true pioneer in understanding the linkage between changes in the gut microbiome and disease. This leadership has put it at the forefront of developing the new biomarkers and diagnostics needed to improve the management of inflammatory bowel and metabolic diseases; two conditions that have been clearly shown to be the result of significant changes to the patients’ gut microbiome.”
“We have been very impressed by the progress that Enterome has made over the last 18 months. We remain very confident that Pierre and his first-class team will be able to leverage both their discovery and clinical expertise in relation to the gut microbiome to generate valuable diagnostic and therapeutic tools that it aims to commercialize in conjunction with leading pharma and diagnostic companies,” added Johan Kordel, senior partner at Lundbeckfond Ventures.
Seventure manages more than €500m, with a focus on digital technologies in France and Germany, and in life sciences all over Europe. It is a subsidiary of Natixis, the corporate investment management and financial services arm of French bank Groupe BPCE.
Launched in December 2013, the firm’s Health for Life Capital fund is the first venture capital fund focused on healthcare, microbiome and nutrition space. The €120m fund has attracted strategic investments from prestigious organisations including Danone, Tereos and Tornier.
Lundbeckfond Ventures is a part of the asset management subsidiary of The Lundbeck Foundation which in addition to substantial financial assets has controlling ownerships in H.Lundbeck, ALK-Abelló and Falck.
Copyright © 2014 AltAssets